This research is being done to find out if paclitaxel works better when given together with an experimental drug called MORAb-003(farletuzumab) or alone in patients with first platinum-resistant or refractory relapsed ovarian cancer

• Drug: MORAb-003 (farletuzumab)
• Drug: 0.9% Saline

• Active Comparator: Paclitaxel with MORAb-003(farletuzumab)
• Placebo Comparator: Paclitaxel with Placebo

Inclusion Criteria:

• Diagnosis of non-mucinous epithelial ovarian cancer measurable by CT or MRI scan, or progression defined by radiologic criteria or by biomarker (CA-125 ≥ 1.5 x ULN) assessed within 4 weeks prior to study entry
• Must have relapsed within 6 months of first or second line platinum-containing chemotherapy. At least one of the lines of chemotherapy must have included a taxane.
• Must have been initially treated with surgery NS first or second line platinum-based chemotherapy;
• Subjects must be candidate for repeat paclitaxel treatment

Exclusion Criteria:

• Clinical contraindications to use of paclitaxel, which include:

  1. persistent Grade 2 or greater peripheral neuropathy
  2. prior hypersensitivity reaction that persisted despite rechallenge with or without desensitization or resulted in bronchospasm or hemodynamic instability or was at least Grade 2 and resulted in medication discontinuation
• Current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas). Note: EOC with prior diagnosis of a low malignant potential tumor that has been surgically resected is acceptable provided the subject did
• Prior radiation therapy is excluded with the exception that it is allowable only if measurable disease for ovarian cancer is completely outside the radiation portal
• Known allergic reaction to a prior monoclonal antibody therapy or have any documented human anti-human antibody (HAHA).
• Previous treatment with MORAb-003 (farletuzumab).